Tema Oncology ETF
Filed by Tema ETF Trust. What this fund reported holding in its latest quarterly NPORT-P. Positions are ordered by share of the fund rather than by size, because that is what separates a conviction from a rounding error.
What it holds
Largest share of the fund first.
| Company | % of fund | Value |
|---|---|---|
| LLYEli Lilly and Co | 5.15% | $10.9M |
| COGTCogent Biosciences Inc | 4.70% | $9.9M |
| RHHBYRoche Holding AG | 4.17% | $8.8M |
| BMYBristol-Myers Squibb Co | 3.57% | $7.5M |
| MRKMerck & Co Inc | 3.56% | $7.5M |
| ABBVAbbVie Inc | 3.32% | $7M |
| HALOHalozyme Therapeutics Inc | 3.19% | $6.7M |
| JNJJohnson & Johnson | 3.09% | $6.5M |
| GMABGenmab A/S | 2.88% | $6.1M |
| EXELExelixis Inc | 2.63% | $5.5M |
| BBIOBridgeBio Pharma Inc | 2.33% | $4.9M |
| AMGNAmgen Inc | 2.06% | $4.3M |
| RLAYRelay Therapeutics Inc | 1.61% | $3.4M |
| KURAKura Oncology Inc | 1.03% | $2.2M |
| GILDGilead Sciences, Inc | 1.02% | $2.1M |
| NTRANatera Inc | 0.93% | $2M |
| GHGuardant Health Inc | 0.66% | $1.4M |
| MRNAModerna Inc | 0.35% | $736.4K |
Source: NPORT-P filings, via EDGAR. Positions arrive by CUSIP, and only a CUSIP verified against a ticker is kept — so this is what we could match, not everything the fund holds, and the matched value is therefore below the fund's own size. A balance is shares where the filing says `NS` and a principal amount where it says `PA`, which is why it is not labelled shares in both cases.
Follow Tema Oncology ETF by email
Tema Oncology ETF's new holdings reports, with the rest of the week's filings. One email a week, free.
Unsubscribe with one click from any email.